X4 Pharmaceuticals Unveils Development Strategy for CXCR4 Inhibitor Pipeline in Cancer Supported by $37.5 million Series A Financing

Company to advance multiple CXCR4 programs focused on cancer immunotherapy, including advancing lead candidate X4P­001 into two clinical
studies in refractory cancers
December 14, 2015 07:00 AM Eastern Standard Time
CAMBRIDGE, Mass.­­(BUSINESS WIRE)­­X4 Pharmaceuticals today announced the launch of the company’s development strategy for its pipeline of C­X­C receptor type 4 (CXCR4 inhibitors), including two clinical studies initiating in 2016 in refractory cancers with its lead drug candidate, X4P­001. The formation of X4 is based on drug compounds that originate from a portfolio of oral CXCR4 inhibitors exclusively licensed from Sanofi.

This entry was posted in Recent Development News: Q4 - 2015, Recent Developments. Bookmark the permalink.
Read Full Article »